Navigation Links
EntreMed to Present at the New York Society of Security Analysts Industry Conference
Date:11/25/2008

ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Company overview will be provided at the NYSSA 2008 Biotech and Specialty Pharmaceuticals Industry Conference, to be held at the Conference Facilities at the NYSSA, New York, December 2, 2008. Dane R. Saglio, Chief Financial Officer, will present on behalf of the Company. The presentation is scheduled for 1:35 p.m. (local time) and will be included in an archived web cast on the NYSSA web site after December 3, 2008. An electronic version of Mr. Saglio's presentation will be available on the Company's web site at www.entremed.com.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

    Ginny Dunn
    Associate Director
    Corporate Communications & Investor Relations
    EntreMed, Inc.
    240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
2. EntreMed Reports Third Quarter 2008 Financial Results
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. EntreMed to Present at BioPartnering Europe Conference
5. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
6. EntreMed Reports Second Quarter 2008 Financial Results
7. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
8. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
9. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Receives Nasdaq Deficiency Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016  PTC Therapeutics, Inc. (NASDAQ: PTCT ... to Realize Innovation, Vision and Empowerment) grant award ... funds to patient advocacy organizations to develop unique ... to the rare disease community by increasing awareness, ... advocates. Mary Frances Harmon , ...
(Date:2/11/2016)... 11, 2016  Vermillion, Inc. (NASDAQ: VRML ), ... announced the formation of the Steering Committee for its ... --> Pelvic masses can present physicians and ... Once pregnancy is ruled out, pelvic masses may include ... endometriosis, benign ovarian tumors and gastrointestinal and urinary tract ...
(Date:2/11/2016)...  Wellcentive today announced it has been selected ... -based community care organization (CCO) with more than ... reporting and care management solutions and services. Wellcentive,s ... quality managers, analysts and care managers while providing ... FamilyCare members. Oregon ...
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant announces ... "Stem Cell Research Products, Opportunities, Tools, and Technologies – ... The ... the stem cell industry, BioInformant has more than a ... stem cell market, by stem cell type. This powerful ...
Breaking Biology Technology:
(Date:1/27/2016)... 2016  Rite Track, Inc. a leading semiconductor equipment ... Chester, Ohio announced today the acquisition of PLUS ... in Austin, Texas , will significantly ... modifications, installations and technical support offerings for TEL Track ... commented, "PLUS has provided world class service including refurbishment, ...
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... -- A market that just keeps on growing. Molecular ... in genomics knowledge. Learn all about it in this ... dynamic trends are pushing market growth and company valuations. ... - pathogen evolution - next generation sequencing - emergence ... of the role of genetic material in Disease and ...
Breaking Biology News(10 mins):